Biolab Pharma has patent approved in the U.S. and competes in BRL 1 billion-per-year market

Revista da Farmácia | 05/06/2021
Biolab Pharma has just been granted a patent in the United States and Mexico for its nail strengthener: Onicut gel. The topical dermocosmetic is now competing in a segment worth more than BRL 1.1 billion per year in the U.S. alone.
 
Cleiton de Castro Marques, CEO of Biolab, explains that this is an important achievement by the company, which focuses on innovation: "We invest 10% of our revenue in research and development to make innovative products available to people in Brazil and other markets. Onicut is the result of that investment."
 
According to the executive, the product – a highlight in Biolab's portfolio – is composed of natural ingredients and has very attractive features for large markets, such as North America and Mexico. In addition, other countries are reviewing the patent application.
 
This is Biolab's second achievement in the international market in 2021. In March, Vonau Flash, a leader in the nausea and vomiting segment, began to be marketed in Colombia after launching in Ecuador.
Learn more
arrow_backward See more articles
Customer Service 0800 724 6522
faleconosco@biolabfarma.com.br
Be connected
Nós usamos cookies e outras tecnologias semelhantes para melhorar a sua experiência, personalizar publicidade e recomendar conteúdo de seu interesse. Ao navegar em nosso site, você está ciente de tal monitoramento. Para mais informações, consulte a nossa nova Política de Privacidade.